Background: The trivalent inactivated split-influenza vaccine, Fluarix TM has been available since 1992. Aim: To assess the safety and immunogenicity of the vaccine from studies in healthy adults ...
The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback